Wang Youdi, Li Jiahong, Guo Jiquan, Wang Qiyou, Zhu Shuguang, Gao Siyuan, Yang Chen, Wei Min, Pan Xuediao, Zhu Wei, Ding Dongmei, Gao Ruiping, Zhang Wei, Wang Junye, Zang Linquan
College of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China.
Guangdong General Hospital, Guangzhou, China.
Planta Med. 2017 Jan;83(1-02):23-29. doi: 10.1055/s-0042-107083. Epub 2016 Jun 10.
Curzerene is a sesquiterpene and component used in oriental medicine. It was originally isolated from the traditional Chinese herbal medicine rhizomes. In this study, anticancer activity of curzerene was examined in both and models. The result of the MTT assay showed that curzerene exhibited antiproliferative effects in SPC-A1 human lung adenocarcinoma cells in a time-dependent and dose-dependent manner. The anticancer ICs were 403.8, 154.8, and 47.0 µM for 24, 48, and 72 hours, respectively. The flow cytometry analysis indicated curzerene arrested the cells in the G2/M cell cycle and promoted or induced apoptosis of SPC-A1 cells. The percentage of cells arrested in the G2/M phase increased from 9.26 % in the control group cells to 17.57 % in the cells treated with the highest dose (100 µM) of curzerene. Western blot and RT-PCR analysis demonstrated that curzerene induced the downregulation of GSTA1 protein and mRNA expressions in SPC-A1 cells. Tumor growth was significantly inhibited in SPC-A1 cell-bearing nude mice by using curzerene (135 mg/kg daily), meanwhile, curzerene did not significantly affect body mass and the organs of the mice, which may indicate that curzerene has limited toxicity and side effects . In conclusion, curzerene could inhibit the proliferation of SPC-A1 human lung adenocarcinoma cells line in both and models. Focusing on its relationship with GSTA1, curzerene could induce the downregulation of GSTA1 protein and mRNA expressions in SPC-A1 cells. Curzerene might be used as an anti-lung adenocarcinoma drug candidate compound for further development.
莪术烯是一种倍半萜烯,也是一种用于东方医学的成分。它最初是从传统中草药根茎中分离出来的。在本研究中,对莪术烯在体外和体内模型中的抗癌活性进行了检测。MTT 试验结果表明,莪术烯在 SPC-A1 人肺腺癌细胞中呈现出时间和剂量依赖性的抗增殖作用。在 24、48 和 72 小时时,其抗癌 IC50 分别为 403.8、154.8 和 47.0 μM。流式细胞术分析表明,莪术烯使细胞停滞于 G2/M 细胞周期,并促进或诱导 SPC-A1 细胞凋亡。停滞于 G2/M 期的细胞百分比从对照组细胞的 9.26%增加到用最高剂量(100 μM)莪术烯处理的细胞中的 17.57%。蛋白质免疫印迹和 RT-PCR 分析表明,莪术烯诱导 SPC-A1 细胞中 GSTA1 蛋白和 mRNA 表达下调。通过使用莪术烯(每日 135 mg/kg),SPC-A1 荷瘤裸鼠的肿瘤生长受到显著抑制,同时,莪术烯对小鼠体重和器官没有显著影响,这可能表明莪术烯具有有限的毒性和副作用。总之,在体外和体内模型中,莪术烯均可抑制 SPC-A1 人肺腺癌细胞系的增殖。着眼于其与 GSTA1 的关系,莪术烯可诱导 SPC-A1 细胞中 GSTA1 蛋白和 mRNA 表达下调。莪术烯可能作为一种抗肺腺癌候选药物化合物用于进一步开发。